• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunitybio Inc (NQ: IBRX )

    6.280 +0.100 (+1.62%)
    Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 766,080
    Open 6.180
    Bid (Size) 6.170 (9)
    Ask (Size) 6.240 (29)
    Prev. Close 6.180
    Today's Range 6.170 - 6.345
    52wk Range 1.250 - 10.53
    Shares Outstanding 391,156,513
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
    Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%). 
    Via Benzinga
    Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga

    Performance

    YTD
    +19.85%
    +19.85%
    1 Month
    +1.29%
    +1.29%
    3 Month
    +9.98%
    +9.98%
    6 Month
    +32.91%
    +32.91%
    1 Year
    +130.88%
    +130.88%

    More News

    Read More
    How Is The Market Feeling About ImmunityBio?
    Via Benzinga
    Check Out What Whales Are Doing With IBRX
    Via Benzinga
    Why ImmunityBio Stock Is Trading Higher Thursday
    Via Benzinga
    KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
    From ImmunityBio, Inc.
    Via Business Wire
    3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions
    Via InvestorPlace
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
    From ImmunityBio, Inc.
    Via Business Wire
    These 3 Interesting Stocks Are Seeing Heavy Short Interest In June 2024
    Via Talk Markets
    Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
    From ImmunityBio, Inc.
    Via Business Wire
    Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
    Via Talk Markets
    IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    The 3 Best Bargain Stocks to Buy in May 2024
    Via InvestorPlace
    Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
    From ImmunityBio, Inc.
    Via Business Wire
    Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells
    Via InvestorPlace
    Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy
    Via Benzinga
    Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
    From ImmunityBio, Inc.
    Via Business Wire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
    From ImmunityBio, Inc.
    Via Business Wire
    Stocks Quietly Climb Ahead Of Central Bank Storm
    Via Talk Markets
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.